钆基对比剂对钠磁共振成像组织钠定量的影响
本研究通过体外稀释实验和琼脂糖样本模拟组织弛豫,并在1例缺血性卒中患者体内评估Dotarem和Gadovist对钠磁共振组织钠定量的影响。结果显示对比剂浓度升高使质子弛豫时间呈双曲线下降、钠弛豫时间多数呈负斜率,最坏情况计算信号下降(1.21%±0.56%),体内组织钠定量差异无统计学意义(P>0.05)。作者建议在临床方案中灵活安排钠成像位置,无需因使用Dotarem或Gadovist而调整。
要点
- 钆基对比剂可缩短钠弛豫时间,但对组织钠定量影响很小。
- 最坏情况计算显示组织钠定量信号下降(1.21%±0.56%)。
- 缺血性卒中患者注射Dotarem前后组织钠定量差异无统计学意义(P>0.05)。
核心结论
- Dotarem和Gadovist对钠弛豫时间有定量影响,但组织钠定量未受损害,最坏情况计算和体内缺血性卒中患者均证实差异无统计学意义(P>0.05)。
研究设计与样本
- 体外稀释实验使用Dotarem和Gadovist与生理盐水稀释至临床浓度范围,并制作琼脂糖样本系列模拟组织弛豫时间行为;体内在1例缺血性卒中患者中评估Dotarem对钠采集和组织钠定量的影响。
关键影像表现/征象
- 质子弛豫时间随对比剂浓度升高呈双曲线函数下降。
- 多数情况下钠弛豫时间在回归分析中呈负斜率。
- 钠T1受影响最大,为每mmol/L对比剂-1.52毫秒。
- 超短回波时间序列信号分析的最坏情况计算显示组织钠定量信号下降(1.21%±0.56%)。
- 缺血性卒中患者注射Dotarem前后脑钠采集显示相关组织和卒中区域的组织钠定量差异无统计学意义(P>0.05)。
临床应用与阅片要点
- 作者建议在临床方案中无论是否使用Dotarem或Gadovist,均可将钠成像安排在有用的临床位置。
- 作者认为灵活的研究方案设计将加强正在进行的针对各种病理的钠成像研究。
局限性
- 体内评估仅在1例缺血性卒中患者中进行。
- 作者建议在临床方案中灵活安排钠成像位置,并认为灵活的研究方案设计将加强正在进行的钠成像研究,提示需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Sodium magnetic resonance (MR) imaging provides noninvasive insights to cellular processes by measuring tissue sodium concentration (TSC). Many clinical studies combine sodium MR imaging with clinical standard MR procedures, in which contrast media is frequently administered. This work investigates the influence of gadolinium-based contrast agents on quantification of TSC. Thus, either scan pauses between early and late contrast-enhanced acquisitions can be used efficiently or sodium imaging can be performed as the final scan after dynamic contrast-enhanced acquisition.
MATERIALS AND METHODS: For this study, 2 gadolinium-based contrast agents, Dotarem and Gadovist, were diluted with saline solution covering contrast agent concentrations in a clinical range. In addition, agarose-based sample series were created to simulate tissue relaxation time behavior. In vivo, the influence of Dotarem on sodium acquisition and TSC quantification was investigated in 1 ischemic stroke patient.
RESULTS: Proton relaxation times decreased for increasing contrast agent concentrations as hyperbolic functions. Sodium relaxation times displayed a negative slope in regression analysis in most cases. The largest influence (-1.52 milliseconds per mmol/L contrast agent) was measured for sodium T1. Worst case calculations in ultrashort echo time sequence signal analysis showed a signal drop of (1.21% ± 0.56%) on tissue sodium quantification. In vivo sodium brain acquisitions of a stroke patient before and after Dotarem injection resulted in statistically nonsignificant differences in TSC quantification of relevant tissues and stroke areas (P > 0.05).
CONCLUSIONS: Our study showed a quantitative influence of Dotarem and Gadovist on sodium relaxation times. However, quantification of TSC was not impaired, which was proven by worst case calculations and nonsignificant differences in vivo in an ischemic stroke patient. We suggest performing sodium imaging in useful clinical positions in protocols regardless of included Dotarem or Gadovist administrations. Being flexible in the study protocol design will strengthen ongoing sodium imaging investigations for various pathologies.
引用
- Paschke NK, Neumann W, Uhrig T, et al. Influence of Gadolinium-Based Contrast Agents on Tissue Sodium Quantification in Sodium Magnetic Resonance Imaging. Invest Radiol. 2018. PMID: 29863602. doi:10.1097/RLI.0000000000000487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。